Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.

LEO Pharma reveals promising phase 2b trial results for temtokibart, a treatment targeting moderate to severe atopic dermatitis effectively.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

Tralokinumab offers a promising alternative for patients with atopic dermatitis experiencing dupilumab-related arthralgia, achieving skin clearance and symptom relief.

Triveni Bio initiates a phase 1 trial for TRIV-509, a promising treatment for atopic dermatitis, targeting key inflammatory pathways.

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

To hear more about AD advancements from Shahriari and Lio in person, register to attend the Revolutionizing Atopic Dermatitis Conference 2025 in Nashville, Tennessee, on June 6 and 7.

Discover the latest advancements in pediatric atopic dermatitis care, featuring expert insights on innovative treatments and family-centered management strategies.

Explore the evolving landscape of dermatology as experts emphasize the importance of cross-specialty collaboration and patient-centered care in aesthetic medicine.

Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch relief.

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

Recent analysis reveals abrocitinib's long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.

New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.

Researchers reported that upadacitinib may lower the incidence of major cardiovascular events and venous thromboembolism in AD.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

At a recent Dermatology Times Case-Based Roundtable event, Lisa Swanson, MD, discussed 3 diverse atopic dermatitis patient cases.

New research reveals JAK inhibitors for atopic dermatitis do not increase cardiovascular or cancer risks compared to IL-4/-13 inhibitors, offering reassurance for patients.

Discover cutting-edge insights on atopic dermatitis at RAD 2025, featuring expert discussions and the latest therapies to enhance your practice.

A new study reveals ongoing burden of moderate to severe atopic dermatitis in youth, with flares, comorbidities, and quality of life impacts.

Explore the effectiveness of basic emollients in treating xerosis cutis associated with atopic dermatitis, enhancing skin hydration and barrier function.

Sophisticated colloidal oat emollients show promise in effectively managing pediatric atopic dermatitis, enhancing skin hydration and reducing flare-ups in infants.

Discover how the RAD conference in Nashville enhances atopic dermatitis care, featuring expert insights and patient-focused strategies for clinicians.

Alexandra Golant, MD discusses how addressing severe, recalcitrant atopic dermatitis remains the most pressing unmet need, with emerging biologics, oral JAK inhibitors, and combination therapies offering promising new approaches for these challenging cases.

Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.

Alexandra Golant, MD discusses how regulatory challenges, ethical considerations in pediatric clinical trials, and limited pharmacokinetic data present significant hurdles for pediatric treatment approvals, while topical ruxolitinib cream's targeted mechanism of action and steroid-sparing benefits make it a meaningful addition for younger children.